17 articles
This post explores how drug manufacturers leverage secondary patents to manage the patent cliff and maintain exclusivity. A detailed analysis of Entresto’s patent timeline and Indian legal context…
The US Supreme Court’s decision in Caraco vs. Novo Nordisk clarifies the rights of generic drug manufacturers to challenge overly broad patent claims. This case marks a significant…
This post discusses recent fines imposed on pharmaceutical companies for pay-for-delay agreements and examines their impact on market competition and drug pricing. It analyses regulatory measures and the…
This post explores evergreening in pharmaceutical patents and how Section 3d of the Indian Patent Act limits patentability for incremental inventions. It discusses the implications for innovation, generic…
This post discusses the legal grounds for granting compulsory licenses when patented drugs are not locally worked in India, as revealed through recent Form 27 compliance issues. It…
Pfizer has sued Watson Laboratories to delay generic Viagra, leveraging the Hatch-Waxman Act and its patents. This case examines Pfizer’s legal strategy and the implications for generic competition…
This article explores how public interest has guided Indian patent law, often supporting generic drug companies over innovators. It argues for a balanced approach to public interest that…
The post explores how brand name drug companies exploit regulatory provisions to maintain market dominance during generic drug challenges. It details the legal and procedural mechanisms involved, focusing…
The UNDP has issued new guidelines aimed at strengthening pharmaceutical patent examination with an emphasis on public health. The guidelines advocate for stricter standards and the use of…
The Lee and BDR decisions signal a shift in the landscape of compulsory licensing in India. This post examines the legal and policy developments leading to these outcomes,…